ARTICLE | Company News
NICE spurns Imbruvica, but opens door to CDF
June 1, 2016 1:19 AM UTC
In draft guidance, the U.K.'s NICE recommended against use of Imbruvica ibrutinib from Johnson & Johnson (NYSE:JNJ) and AbbVie Inc. (NYSE:ABBV) to treat chronic lymphocytic leukemia (CLL) in patients without a 17p deletion or TP53 mutation, but invited J&J to submit a proposal for the drug's inclusion in the new Cancer Drugs Fund to treat CLL patients with those mutations.
Also on Tuesday, AbbVie said the European Commission (EC) approved Imbruvica as a first-line treatment for adults with CLL. The EC had already approved Imbruvica as a first-line treatment for CLL patients who had 17p deletion or TP53 mutation, or as second-line CLL therapy. ...